Athenex Announces the Addition of David Cutler, MD, FRCP(C) to its Global Clinical Development Team
BUFFALO, N.Y. and HONG KONG, April 4, 2016 /PRNewswire/ -- Athenex, Inc. announced today that David Cutler, MD, FRCP(C), has joined Athenex as Vice President of Clinical Development working together with Dr. Rudolf Kwan, Chief Medical Officer.
Dr. Cutler has extensive expertise in oncology drug development including a recent leadership position as Distinguished Clinical Scientist, Translational Pharmacology in Merck, serving as the lead for Oncology Pharmacology. Previously he held senior positions in Early Clinical Research and Experimental Medicine in Schering-Plough Research Institute and in Clinical Research at Schering-Plough Japan. Dr. Cutler graduated from the University of Saskatchewan Medical School, is Board certified in Internal Medicine, Endocrinology and Metabolism, and is a Fellow of the Royal College of Physicians of Canada. Dr. Cutler stated, "Athenex intrigued me with their strong pipeline of oral oncology molecules. Athenex has a deep and experienced executive management team and is evolving as a fully integrated oncology specialty pharmaceutical platform in both the USA and Asia. A number of products in the pipeline are in late-stage development which fits well with my previous professional experience. I look forward to contributing to the team and am delighted to have a chance to create new treatment options for patients with cancer."
Dr. Rudolf Kwan commented, "David is a top-notch expert in the clinical development of oncology drugs and adds depth to our existing global team. His expertise and leadership will help the advancement of our extensive oncology drug pipeline, which currently consists of 7 clinical candidates including 6 in trials authorized under US INDs. David's background is ideally suited to add immediate value to our late-stage development plans. We have 20 clinical studies around the world that are active or anticipated to launch during 2016. Our team extends our very warm welcome to David."
Dr. Jinn Wu, Board Member of Athenex, said, "David is an excellent addition to our management team. His expertise complements well our existing product development team. The Board is confident that he will quickly integrate and contribute substantially to our clinical development execution."
About Athenex, Inc.
Founded in 2003, Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies with a particular emphasis on the China and U.S. markets. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes: three portfolios of innovative proprietary products under development, medical technology research innovation centers, product development and regulatory teams and existing manufacturing facilities in China and the U.S. Our employees include several hundred dedicated professionals to the mission of improving the lives of cancer patients throughout the world. With our connected innovation, development and manufacturing presence concentrated in China and the US, we can identify, develop, and deliver unique medical technology across continents and multiple regulatory environments. We have offices in: Buffalo and Clarence New York, Cranford New Jersey, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China. In addition to our offices, we have regional development partners in Dunedin New Zealand, Hong Kong, Guangzhou China, Seoul South Korea, Taipei Taiwan, Guatemala City, Guatemala, and Buenos Aires Argentina.
SOURCE Athenex, Inc.
Share this article